P154 TRPV1 is not a Target for the Treatment of non-allergic Rhinitis: A Clinical Study. (19th November 2012)

• Record Type: Journal Article
• Authors: Murdoch, RD; Bareille, P; Bentley, J; Newlands, A; Smart, K; Patel, D
• Is Part Of: Thorax. Volume 67(2012)Supplement 2
• Page Start: A129
• Page End: A129
• Publication Date: 2012-11-19
• Subjects: Chest -- Diseases -- Periodicals; Thorax; Chest -- Diseases; Periodicals; Periodicals; 617.54
• DOI: 10.1136/thoraxjnl-2012-202678.215
• Languages: English
• ISSNs: 0040-6376

Abstract

Abstract : Background: TRPV1 is a ligand gated ion channel activated by a range of physiological factors such at Temperature, pH, and osmotic stress. In the nose, the TRPV1-expressing sensory c-fibres are thought to play a key role in the development of nasal hyper-responsiveness resulting in symptoms in NAR patients. We hypothesise that topical antagonism with a selective TRPV1 antagonist would offer substantial symptom control. SB705498 is a potent selective TRPV1 antagonist in animal and human models. Methods: 40 M&F NAR patients were enrolled into a randomised, double-blind, placebo controlled, 2 period crossover study of either 12mg SB705498 i.n. or placebo for 14 days with a 4 week washout. The study was conducted in a validated Environmental Challenge Chamber (Cetero) where patients were exposed to Cold Dry Air (CDA) at 14c, 15% RH, air speed 5 feet/sec. Exposure was over the winter months in Canada. Diary card symptoms were analysed during home dosing on days when the temp was less than 14c. Two chamber sessions of 1hr duration, as well as medical history and neg skin prick testing, at screening were performed to establish a consistent diagnosis with a single challenge on Day 1+1hr, Day14+1hr and Day 14+24hr to establish the drug response. Post dose TSS (rhinorrhoea, congestion, PND), sneezing and ocular symptoms were recorded, as was acoustic rhinomanometry, RQLQ, PK and Safety monitoring. Results: The primary outcome of weighted mean TSS over the challenge period or the maximum TSS was not impacted by administration of SB705498 relative to placebo (see figure ). There was no impact on sneezing, ocular symptoms, acoustic rhinimanometry, or RQLQ Compared with placebo, repeated doses of SB705498 did not alleviate TSS triggered by cold in a multistimuli wild type setting. PK analysis supported an o.d. regimen with 2 fold accumulation over the dosing period. Conclusions: In a robust clinical model of non-allergic rhinitis, intranasal SB705498 12mg o.d. for 14 days did not alleviate the symptoms of NAR triggered by the most common provocation agent: Cold Dry Air. We conclude that despite engagement of the TRPV1 receptor there was no translation to clinical efficacy, suggesting redundancy in symptom pathways.